China Diabetes Drug Market Report

Diabetes Mellitus (DM) is a chronic disease that occurs when the pancreas does not produce enough insulin, or alternatively, when the body cannot effectively use the insulin it produces.

When China started its economic reform in 1978, the diabetes disease rate was about 0.6% in the Chinese population. As China entered the rapid growth phase of its economic development, the diabetes disease rate has arisen rapidly. In 1995, the diabetes disease rate reached 1.5% and in 2000 the diabetic disease rate was 2.4% with the total number of diabetes patients at 31 million in China. The average addition of new diabetes patients each year was about 1.5 millions. Due to the increased numbers of diabetes patients and the improvements of living standards, the market size of anti-diabetic drugs has increased steadily in China. The market size of anti-diabetic drugs in 2002 was about RMB 4.187 billion and increased to RMB 7.495 billion in 2007 (USD 1.071 billion at 7:1 USD:RMB exchange rate) with an average annual growth of 13%. The annual growth rate from 2006 to 2007 was a significant 20.98%.

This report has systemically analyzed the Chinese anti-diabetic drug market. All market estimates of drug utilization in China are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major anti-diabetics products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major anti-diabetic drugs will present you a clear picture of the competition landscape of Chinese anti-diabetics drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Anti-diabetic Drug Market Report has been indispensible references for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.